Press releases

* (R) = Regulatory press releases

Jul 17, 2014

(R) Cantargia gears up with new CEO and substantial capital injection
Jan 15, 2014

(R) Cantargia receives capital injection and attracts new board members
Jul 4, 2013

(R) Sunstone Capital and LU Bioscience invest 7 MSEK in Cantargia
Jul 11, 2012

(R) Cantargia granted patent in the UK for the medical use of IL1RAP modulators
Feb 2, 2012

(R) In-vivo proof of concept achieved by targeting of IL1RAP on human tumor
Jan 30, 2012

(R) Attention on Cantargia in BioCentury
Sep 20, 2011

(R) Cantargia co-founder to present at International Conference on Chronic Myeloid Leukemia
Feb 21, 2011

(R) Cantargia builds power
<< Newer press releases   

In media

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye

CONTACT US
Cantargia AB
Scheelevägen 27
SE-223 63 Lund, Sweden

E-mail: info@cantargia.com
Switch board: +46(0)46 2756260

Privacy Policy

Subscribe to our press releases

© Copyright 2026 · Cantargia AB